Blue Jet Healthcare Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ykcaasces5boluwlydoe6b4w.pdf

Key Takeaways


The Mahad Incident: Impact, Response & Recovery Timeline

Shiven Arora: "Our foremost concern was the loss of life due to the accident which can never be compensated."

Pharma Intermediate: The Cardiovascular Molecule Bet

VK Singh: "We are, however, sticking to the original projections that we had discussed about and not factoring in any of this uptick that could come from the label updation that's happened."

Contrast Media: Near-Term Softness, Structural Tailwinds

Shiven Arora: "Today in some of the select intermediates in contrast media, we have a world leadership position. To an extent, if there is a requirement and spare capacity, we will export to China."

Artificial Sweeteners: A Price War Blue Jet Won't Fight


Margins: Current Strength, Future Normalization

Shiven Arora: "I think the prediction right now is fairly conservative. I think we want, firstly, the capex that we are doing for backward integration to stabilize. The catch-up could be aggressive as well."

Capacity Build-Out & Capex: Laying the Pipes for FY25–26


Guidance & Commitments

CommitmentSpecificsTimeline
Insurance claim reversalReversal of property loss hit in P&L once insurer admits claimQ4 FY24 to Q1 FY25
Contrast media recoveryStrong recovery to begin, driven by NCE intermediate ramp-upsQ1 FY25
New contrast media product commercial volumesStart of commercial volumes upon completion of customer regulatory processQ2–Q3 FY25
Cardiovascular intermediate volume uptickSignificant uptick when new USFDA-approved capacity in Unit 2 comes on streamQ1 FY25
MRI NCE intermediate commercial offtakeCommercial offtake to increaseQ2 FY25
Generic iodinated intermediate ramp-upSignificant ramp-up (conservative estimate)Q2–Q3 FY25
Mahad backward integration block validationBlock validatedQ3 FY25
Mahad multipurpose block validationBlock validatedQ1 FY26
Greenfield site facilityFacility expectedFY26
PI API revenue scale-upFrom INR 30–34 crores to 10x–15xTwo to three years
Gross margin medium-term levelNormalization to around 55%Medium term (post backward integration capex stabilization)
Sweetener dumping pressureTrend may last another two to three quarters; company will not enter price warTwo to three quarters
FY25 capexApproximately INR 200–220 croresFY25

Key Metrics

MetricQ3 FY24
Total turnoverDropped by 1% YoY
Contrast media revenueDe-grew by 8% YoY; grew 8% in 9M FY24
Artificial sweetener revenueDe-grew by 35% YoY; de-grew 33% in 9M FY24
Pharmaceutical intermediate revenueGrew by 250% YoY; grew 194% in 9M FY24
Gross margin57.5% for 9M FY24; sustainable at 57–58% for a couple of quarters, medium-term around 55%
Profit After TaxDropped to 19% in Q3; 23% for 9M FY24 including extraordinary item, compared to 21% in previous year
Extraordinary itemIn excess of ₹3 cr compensation paid to families of casualties, plus property damage loss at Mahad
Cash and investments₹237 cr as of 31 December
Capex incurred (FY24)~₹160 cr expected for FY24, with Mahad investments pushed to FY25
Capex guidance (FY25)₹200 cr to ₹220 cr targeted for next financial year
Ambernath Unit 2 capex₹90 cr to ₹100 cr outlay, validation expected in Q1 FY25
Mahad total capex outlay~₹250 cr, split between backward integration block and multipurpose CDMO block
Solar project investmentClose to ₹30 cr, completed December 2023, integrated with grid by January 2024
Renewable energy shareMore than 60% of total power requirement expected from solar
Delivery timelines60 to 70 days currently, compared to normal 35 to 40 days, due to Red Sea situation